Advertisement
Screener

ALDEYRA THERAPEUTICS, INC. (ALDX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

2.3 / 5 stars · 18/40 Roast Me

ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 670.82 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06

  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 278.66K shares.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 392.16K shares.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 8.94K shares, a 97.15% decline year-over-year.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 124.72K shares, a 63.85% decline from fiscal 2024.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 344.99K shares, a 14.70% increase from fiscal 2023.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 300.77K shares, a 59.26% decline from fiscal 2022.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 738.22K shares, a 133.32% increase from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2026-06-30278.66K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
670.82K shares
10-Q · filed 2026-08-06
679.76K shares
derived: sum of 3 quarters · filed 2026-08-06
679.76K shares
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31392.16K shares
10-Q · filed 2026-05-07
401.10K shares
derived: sum of 2 quarters · filed 2026-05-07
401.10K shares
derived: sum of 3 quarters · filed 2026-05-07
2025-12-318.94K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
8.94K shares
derived: sum of 2 quarters · filed 2026-02-27
124.72K shares
10-K · filed 2026-02-27
2025-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
115.78K shares
10-Q · filed 2025-11-05
2025-06-30115.78K shares
10-Q · filed 2025-08-07
2024-12-31313.48K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
313.48K shares
derived: sum of 2 quarters · filed 2025-02-28
313.48K shares
derived: sum of 3 quarters · filed 2025-02-28
344.99K shares
10-K · filed 2025-02-28
2024-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
0.00 shares
derived: sum of 2 quarters · filed 2024-11-07
31.51K shares
10-Q · filed 2024-11-07
232.44K shares
derived: sum of 4 quarters · filed 2024-11-07
2024-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
31.51K shares
10-Q · filed 2024-08-01
232.44K shares
derived: sum of 3 quarters · filed 2024-08-01
2024-03-3131.51K shares
10-Q · filed 2024-05-02
232.44K shares
derived: sum of 2 quarters · filed 2024-05-02
2023-12-31200.94K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07
300.77K shares
10-K · filed 2024-03-07
2023-09-3099.83K shares
10-Q · filed 2023-11-03
2022-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
258.39K shares
derived: sum of 2 quarters · filed 2023-03-09
738.22K shares
10-K · filed 2023-03-09
2022-09-30258.39K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
738.22K shares
10-Q · filed 2022-11-10
2022-06-30479.83K shares
10-Q · filed 2022-08-05
2021-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
0.00 shares
derived: sum of 2 quarters · filed 2022-03-17
0.00 shares
derived: sum of 3 quarters · filed 2022-03-17
316.40K shares
10-K · filed 2022-03-17
2021-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
0.00 shares
derived: sum of 2 quarters · filed 2021-10-28
316.40K shares
10-Q · filed 2021-10-28
673.61K shares
derived: sum of 4 quarters · filed 2021-10-28
2021-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
316.40K shares
10-Q · filed 2021-08-05
673.61K shares
derived: sum of 3 quarters · filed 2021-08-05
732.19K shares
derived: sum of 4 quarters · filed 2021-08-05
2021-03-31316.40K shares
10-Q · filed 2021-05-06
673.61K shares
derived: sum of 2 quarters · filed 2021-05-06
732.19K shares
derived: sum of 3 quarters · filed 2021-05-06
1.17M shares
derived: sum of 4 quarters · filed 2021-05-06
2020-12-31357.21K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
415.80K shares
derived: sum of 2 quarters · filed 2021-03-11
852.80K shares
derived: sum of 3 quarters · filed 2021-03-11
1.04M shares
10-K · filed 2021-03-11
2020-09-3058.58K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
495.58K shares
derived: sum of 2 quarters · filed 2020-11-05
678.07K shares
10-Q · filed 2020-11-05
950.97K shares
derived: sum of 4 quarters · filed 2020-11-05
2020-06-30437.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
619.49K shares
10-Q · filed 2020-08-06
892.38K shares
derived: sum of 3 quarters · filed 2020-08-06
1.00M shares
derived: sum of 4 quarters · filed 2020-08-06
2020-03-31182.49K shares
10-Q · filed 2020-05-07
455.38K shares
derived: sum of 2 quarters · filed 2020-05-07
566.44K shares
derived: sum of 3 quarters · filed 2020-05-07
2019-12-31272.90K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
383.95K shares
derived: sum of 2 quarters · filed 2020-03-12
404.48K shares
10-K · filed 2020-03-12
2019-09-30111.06K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
131.59K shares
10-Q · filed 2019-11-07
2019-06-3020.53K shares
10-Q · filed 2019-08-09
2018-12-312.08K shares
10-K · filed 2019-03-08
2018-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
0.00 shares
10-Q · filed 2018-08-09
0.00 shares
derived: sum of 3 quarters · filed 2018-08-09
123.78K shares
derived: sum of 4 quarters · filed 2018-08-09
2018-03-310.00 shares
10-Q · filed 2018-05-15
0.00 shares
derived: sum of 2 quarters · filed 2018-05-15
123.78K shares
derived: sum of 3 quarters · filed 2018-05-15
151.06K shares
derived: sum of 4 quarters · filed 2018-05-15
2017-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29
123.78K shares
derived: sum of 2 quarters · filed 2018-03-29
151.06K shares
derived: sum of 3 quarters · filed 2018-03-29
151.06K shares
10-K · filed 2018-03-29
2017-09-30123.78K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
151.06K shares
derived: sum of 2 quarters · filed 2017-11-09
151.06K shares
10-Q · filed 2017-11-09
286.07K shares
derived: sum of 4 quarters · filed 2017-11-09
2017-06-3027.28K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
27.28K shares
10-Q · filed 2017-08-07
162.28K shares
derived: sum of 3 quarters · filed 2017-08-07
180.94K shares
derived: sum of 4 quarters · filed 2017-08-07
2017-03-310.00 shares
10-Q · filed 2017-05-15
135.00K shares
derived: sum of 2 quarters · filed 2017-05-15
153.66K shares
derived: sum of 3 quarters · filed 2017-05-15
162.69K shares
derived: sum of 4 quarters · filed 2017-05-15
2016-12-31135.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30
153.66K shares
derived: sum of 2 quarters · filed 2017-03-30
162.69K shares
derived: sum of 3 quarters · filed 2017-03-30
171.16K shares
10-K · filed 2017-03-30
2016-09-3018.66K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14
27.69K shares
derived: sum of 2 quarters · filed 2016-11-14
36.16K shares
10-Q · filed 2016-11-14
2016-06-309.03K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10
17.50K shares
10-Q · filed 2016-08-10
2016-03-318.47K shares
10-Q · filed 2016-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
iBio, Inc. (IBIO)United States$0.077B-2.94
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30